Pamodi ki é difísil atxa un algen ki ten kánser di próstata?
Kanseru di próstata é sugundu kazu di kankru más komun na ómis na mundu interu, ku un estimativa di 1.276 milhons di kazu novu relatadu na 2018, ki ta riprizenta 7.1% di tudu kazus di kankru na ómis.
Taxa di mortalidadi pa kankru di próstata ê altu, ku un estimativa di 37.005 morti na mundu interu na 2018.
Má taxa di mortalidadi ta varia txeu di un rijion pa otu, ku Áfrika Osidental ku quintu risku más altu di mortalidadi di kankru di próstata na mundu, y Nigéria ku más grandi populason y ekonomia na kel rijion.
Na Nigéria, kankru di próstata é mutu más kumun y más mortal pa ómis, ku un estimativa di 32.8 kazus y 16.3 morti pa kada 100,000 ómis.
Kel-li é más di dôs bês más txeu ki taxa di mórti na Mérka di Nórti.
Deteson tardi di duensa, limitason di rekursus pa screening y deteson, y diminuison di dukumentason y rilatamentu di kazus ta kontribui pa altu taxa di mortalidadi na Nigéria.
Na Merka, cancer di próstata é sugundu kauzas di morti mas komun di homis, ku serka di 40 mil ómis ki ta morri di es duensa tudu anu.
Morti pa kankru di próstata ba ta diminui poku-poku désdi inísiu di anus 90, má e ta kontinua un prubléma di saúdi.
Pur tudu, kanser di próstata é un duénsa mortal, partikularmenti na rijions ku asesu limitadu a kuidadus médikus y rikursus di screening.
Má, odja i trena kes duénsa sédu pode midjora txeu i poi algen ta móre más poku.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Diskrison: médiku']
['Es site é sô pa studa i pa da informason.']
['Kes informason li ka debe uzadu pa faze diagnóstiku ô pa kura algun prubléma di saúdi.']
['Pur favor, toma nota ma redi neuronal ki ta jenera respóstas pa perguntas, é spesialmenti inakuradu óras ki ta papiadu di konteúdu numériku. Pur izénplu, nunbru di pesoas diagnostikadu ku un duénsa spesifiku.']
['Sénpri buska konsedju di bu médiku ó otu prestador di kuidadu di saúdi kualifikadu sobri un kondison médiku. Nunka ka bu nega konsedju di médiku profisional ô atrasa na buska-l pamodi algun kuza ki bu lé na es pájina. Si bu atxa ma bu pode ten un imerjénsia médiku, txoma 911 ô bai pa kuartu di imerjénsia más pértu imediatamenti.']
['Diskubri autor']
['Lei di Direitus Umanu Digital di 1998, 17 U.S.C. § 512 (o DMCA) ta dispunibiliza rikursus pa titular di direitus ki ta atxa ma material ki ta parsi na Internet ta viola ses direitus di akordu ku lei di direitus di autor di Stadus Unidus. ']
['Si bu kré, di bon fé, ki kualker kontiudu ô material disponibilizadu na nos site ô servisus ta viola bu direitus di autor, bo (ô bu ajenti) podi manda-nu un avizu ta pidi pa retiradu ô blokia es konteúdu ô material.']
['Nu ten ki manda un mensaji pa email (odja "Contact" pa kel email).']
['Es lei ta iziji ki bu notifikason di alegadu violason di copyright inklui kes siginti informason: (1) un deskripson di obra protejedu pa copyright ki e sujetu di alegadu violason; (2) un deskripson di kel konteúdu alegadu y informason sufisienti pa permiti-nu lokaliza kel konteúdu; (3) informason di kontatu pa bo, inkluindu bu enderesu, númeru di tilifon i enderesu di email; (4) un deklarason di bo ki ten un bon fé ma kel konteúdu di forma reklamadu ka e autorizadu pa donu di copyright, o pa se ajenti, o pa kualker lei; ']
['5. un deklarason di bu senhoriu, asinadu sob pena di perjúriu, ma informason na notifikason é izatu y ma bu ten autoridadi pa pratika kel direitu di autor ki foi violadu;']
['i (6) un asinatura fíziku ô iletróniku di kel algen ki é donu di direitus di autor ô di un algen ki sta autorizadu pa aji na se nómi.']
['Si bu ka da tudu informason, kel informason pode dimora txeu ténpu.']
['Kontaktu di Grupu']
['Pur favor, manda-nu email ku kalker pergunta/sugeston.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na kel ténpu']
['BioMedLib ta uza konputador automatizadu (algoritmus di aprendizagen di mákina) pa gera pares di pergunta y rasposta.']
['Nu ta kumesa ku 35 milhon di publikason biomédicu di PubMed/Medline. tanbê pájinas di internet di RefinedWeb.']
